iodine-131-labeled extracellular vesicles

Iodine-131-labeled extracellular vesicles (also known as 131I-ABPC-EVs) is a radiolabeled diagnostic imaging agent developed by Xijing Hospital and the Fourth Military Medical University. It consists of extracellular vesicles (EVs) derived from antler blastemal progenitor cells (ABPCs) labeled with the radioactive isotope iodine-131 (131I) using the Iodogen method. The agent is designed for SPECT/CT imaging to evaluate the in vivo biodistribution, pharmacokinetics, and dosimetry of ABPC-derived extracellular vesicles, which have shown therapeutic potential in mitigating aging-related phenotypes, improving motor and cognitive functions, and reducing systemic inflammation. Preclinical studies, including first-in-monkey SPECT/CT imaging, have demonstrated high in vitro stability and clear visualization of the cardiac blood pool and physiological uptake in the liver and nasal cavity, facilitating the clinical translation of therapeutic EVs.

Other names

131I-ABPC-EVs131I-EVs131I-labeled aging targeted extracellular vesicles131I-labeled antler blastemal progenitor cell-derived extracellular vesicles131I-labeled extracellular vesicles131I-labeled targeted EVsiodine-131-labeled antler blastemal progenitor cell-derived extracellular vesiclesiodine131-labeled antler blastemal progenitor cell-derived extracellular vesiclesiodine 131-labeled antler blastemal progenitor cell-derived extracellular vesicles